English
One of the promising directions in modern nanomedicine comprises the self-assembly of amphiphilic copolymers to construct functional nano-architectures. Such objects are already exploited in biomedical applications as nano-containers for controlled substance delivery, robust biocompatible coatings, etc. Work in this field may be classified as bio-inspired as such type of organization is typical for naturally occurring entities. In this project we apply our expertise in macromolecular science to search for new pharmaceutical strategies in nanomedicine. We believe that rationally designed synthetic macromolecules can serve as novel antiviral medicines, detoxification agents and drug carriers through the formation of polymer-virus and polymer-polymer complexes. Our ultimate goal is to obtain a fundamental understanding of specific mechanisms of interaction between artificially designed and biological nano-objects and to develop the guidelines for novel therapies based on this knowledge. We attack this problem by synthesis of novel copolymers, the study of the physical-chemical (and pharmaceutical) properties of the mesoscopic structures that they form as well as how they interact with selected viruses. A theoretical analysis of these issues will assist in the interpretation of experimental findings and in the coordination of the polymer synthesis program. As a result of our cumulative synthetic efforts (groups RUS3, RUS4) and comprehensive multi-level studies including: (i) theoretical analysis of polymer-virus assemblies and copolymer micelles of complex architecture (groups RUS1, RUS2, RUS3, NL1), (ii) physical-chemical characterization of self-organizing nano-structures in solutions (groups RUS4, NL1), and (iii) in vitro testing of performance (groups RUS3, NL2), we anticipate the creation of: (a) a novel family of copolymers and derivative substances tailored for a wide-spectrum of antiviral protection and tested in the laboratories with respect to both, the efficiency and pharmo-technological capabilities; (b) model nano-scale pharmaceuticals (virus-responsive inhibitors and traps as well as stimuli-responsive delivery systems) obtained on the basis of new generation of block, gradient and graft-modified copolymers, characterized and tested with respect to their biocompatibility and bioselective performance. The advantage of the macromolecular approach over the traditional small molecule therapeutics would be a higher efficiency, a wider spectrum of action and the possibility to re-design existing nano-pharmaceuticals for new emerging targets. We anticipate that results of our research will have a profound impact on the fields of general medicine, immunology and drug-design technology, physics and chemistry of macromolecules. In the long term it could lead to novel effective means of protection (treatment) of the human population from a variety of life-threatening diseases worldwide.The reputation of the groups involved and the long experience of cooperation guarantees its productivity and impact.
